Lirum Therapeutics (Lirum Therapeutics) Operating Cash Flow per Share : $-0.03 (TTM As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Lirum Therapeutics Operating Cash Flow per Share?

Lirum Therapeutics's operating cash flow per share for the three months ended in Dec. 2023 was $0.00. Lirum Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.03.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Lirum Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

LRTX's 3-Year OCF Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.3
* Ranked among companies with meaningful 3-Year OCF Growth Rate only.

Lirum Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for Lirum Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lirum Therapeutics Operating Cash Flow per Share Chart

Lirum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Operating Cash Flow per Share

-0.03

-0.24

Lirum Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Sep23	Dec23
Operating Cash Flow per Share	-	-	-0.03	-	-

Competitive Comparison of Lirum Therapeutics's Operating Cash Flow per Share

For the Biotechnology subindustry, Lirum Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lirum Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lirum Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Lirum Therapeutics's Price-to-Operating-Cash-Flow falls into.

Lirum Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Lirum Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-2.241	/	9.270
	=	-0.24

Lirum Therapeutics's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	0	/	9.270
	=	0.00

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03

Lirum Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Lirum Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Lirum Therapeutics (Lirum Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lirum Therapeutics Inc (NAS:LRTX) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

590 Madison Avenue, 21st Floor, New York, NY, USA, 10022

Website

https://www.lirumtx.com

Lirum Therapeutics Inc is clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development, and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways, and commercial opportunities. Its product candidate, LX-101, formerly 765IGF-MTX, is a novel, clinical-stage, "next generation," precision-engineered targeted therapy directed to the IGF-1R.

Lirum Therapeutics (Lirum Therapeutics) Headlines

No Headlines